Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A randomized, double blind study of the safety and efficacy of GSK1349572 50mg once daily to raltegravir 400mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects
dolutegravir
ING113086
NCT01227824
Infection, Human Immunodeficiency Virus I
Phase 3
 
January 2014

Powered by ideaPoint, Inc.